BeiGene fur­ther in­vests in AD­Cs with sol­id tu­mor part­ner Du­al­i­ty­Bio, a BioN­Tech col­lab­o­ra­tor

BeiGene is ex­pand­ing its can­cer ar­se­nal with an an­ti­body-drug con­ju­gate deal, en­list­ing the same Shang­hai biotech that teamed up with BioN­Tech in April.

The sol­id tu­mor part­ner­ship with Du­al­i­ty­Bio will help BeiGene broad­en its ear­ly-stage pres­ence in the ADC field. The space has grown with the suc­cess of As­traZeneca and Dai­ichi Sankyo’s breast can­cer treat­ment En­her­tu, Pfiz­er’s planned $43 bil­lion ac­qui­si­tion of Seagen, and a se­ries of in­dus­try col­lab­o­ra­tions look­ing to make the next big dent in on­col­o­gy.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER